Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Total Debt (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Total Debt for 6 consecutive years, with $37944.0 as the latest value for Q2 2025.

  • Quarterly Total Debt fell 75.07% to $37944.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $37944.0 through Jun 2025, down 75.07% year-over-year, with the annual reading at $110517.0 for FY2024, 26.37% down from the prior year.
  • Total Debt for Q2 2025 was $37944.0 at Inhibikase Therapeutics, down from $74772.0 in the prior quarter.
  • The five-year high for Total Debt was $248911.0 in Q1 2021, with the low at $37944.0 in Q2 2025.
  • Average Total Debt over 5 years is $146537.4, with a median of $147433.5 recorded in 2023.
  • The sharpest move saw Total Debt grew 4.92% in 2023, then crashed 75.07% in 2025.
  • Over 5 years, Total Debt stood at $248911.0 in 2021, then crashed by 41.41% to $145836.0 in 2022, then increased by 2.92% to $150095.0 in 2023, then decreased by 26.37% to $110517.0 in 2024, then crashed by 65.67% to $37944.0 in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $37944.0, $74772.0, and $110517.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.